Barry Ticho Sells 10,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $13.75, for a total value of $137,500.00. Following the transaction, the insider now owns 2,485 shares of the company’s stock, valued at $34,168.75. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Stoke Therapeutics Trading Down 1.2 %

STOK stock traded down $0.16 during trading hours on Wednesday, hitting $12.67. 336,169 shares of the stock traded hands, compared to its average volume of 929,800. The stock has a 50-day simple moving average of $13.91 and a 200 day simple moving average of $9.56. Stoke Therapeutics, Inc. has a one year low of $3.35 and a one year high of $17.58. The company has a market cap of $660.36 million, a P/E ratio of -5.49 and a beta of 0.87.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, May 6th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.03. The firm had revenue of $4.22 million for the quarter, compared to the consensus estimate of $3.33 million. Analysts forecast that Stoke Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently modified their holdings of STOK. Trexquant Investment LP lifted its holdings in shares of Stoke Therapeutics by 166.9% during the third quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after purchasing an additional 79,785 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in shares of Stoke Therapeutics during the third quarter valued at $48,000. GSA Capital Partners LLP lifted its stake in Stoke Therapeutics by 514.7% in the 3rd quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock worth $1,371,000 after acquiring an additional 291,443 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in Stoke Therapeutics in the 3rd quarter worth about $64,000. Finally, Los Angeles Capital Management LLC increased its position in Stoke Therapeutics by 30.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 62,257 shares of the company’s stock worth $327,000 after purchasing an additional 14,510 shares during the last quarter.

Analyst Upgrades and Downgrades

STOK has been the subject of a number of recent research reports. Canaccord Genuity Group lowered their price objective on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Wedbush increased their price target on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. TD Cowen raised Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.57.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.